ARTICLE | Emerging Company Profile
Suppressing somatostatin
How Zucara's SSTR2 antagonists could prevent hypoglycemia in T1D patients
November 18, 2016 6:38 PM UTC
Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy.
In Type I diabetes, somatostatin production is elevated, leading to continuous inhibition of glucagon. Glucagon inhibition in turn prevents patients from increasing and normalizing blood glucose levels following insulin therapy. ...
BCIQ Company Profiles
BCIQ Target Profiles